Growth Factor News and Research

RSS

Obesity is linked to lower levels of prostate specific antigen (PSA) in men

A study reported in the current issue of Cancer, the journal of the American Cancer Society, shows that obesity is linked to lower levels of prostate specific antigen (PSA) in men, making early detection tests unreliable.

24 Jan 2005

New ideas for creating a new generation of oral medications to treat infertility

Researchers now have a much better picture of how follicle-stimulating hormone (FSH), one of the most frequently used fertility drugs, works, and with it new ideas for creating a new generation of oral medications to treat infertility.

20 Jan 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Tobacco smoke triggers the production of COX-2

Tobacco smoke triggers the production of COX-2, a cellular protein linked to the development and progression of cancer, according to research published in the January 15 issue of the journal Cancer Research.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Novel approach to bioengineer artificial skin for burn victims

Each year more than 45,000 Americans suffer burns serious enough to require a hospital stay, according to the American Burn Association. While the traditional therapy of using skin grafts to cover burn sites has improved, a number of problems including scarring, infection and poor adhesion remain.

4 Jan 2005

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD), according to a paper in the Dec. 30 issue of the New England Journal of Medicine. Macugen was approved by the Food and Drug Administration on Dec. 17.

30 Dec 2004

Tercica files for patent infringement

Tercica announced today the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Virginia and Avecia Limited of the United Kingdom.

20 Dec 2004

European market for bone morphogenic proteins in spine fusion

High growth is forecast for novel technologies used either as adjuncts or as alternatives to current surgical procedures for the fusion of spinal vertebrae. Bone morphogenic proteins (BMP) - a new and innovative class of natural growth factors - represent amongst the most exciting of these niches.

20 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development

Because up to 75 percent of breast cancer patients have an abnormality in a specific cell signaling pathway, drugs that target different molecules along that pathway may be especially effective for treating the disease, says a researcher from The University of Texas M. D. Anderson Cancer Center.

13 Dec 2004

Model may explain how alcohol stimulates tumor growth

The investigators found that compared to the saline control group, the embryos exposed to ethanol experienced increases in tumor size, tumor blood vessel density, cancer cell infiltration of blood vessels, and VEGF levels.

13 Dec 2004

Thiazolidinedione (TZD) class of anti-diabetic drugs may be a potential targeted therapy for myeloma patients

In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients.

8 Dec 2004

Class of cells that arises in mammary glands during maternity has stem cell-like properties

These parity-induced mammary epithelial cells (PI-MEC) have the ability to self-renew over many generations and to differentiate into numerous cellular subtypes.

7 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

New trial to test cancer smart drugs

Cancer Research UK has launched a major new clinical trial for the most common form of lung cancer, to test the effectiveness of one of the new generation of 'smart' cancer drugs as a first line treatment.

29 Nov 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Growth Factor News and Research

Obesity is linked to lower levels of prostate specific antigen (PSA) in men

New ideas for creating a new generation of oral medications to treat infertility

Research leads to new antiangiogenic drugs

Avastin available across Europe within the next few weeks

Tobacco smoke triggers the production of COX-2

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Potential new therapies for cancer and bleeding disorders

Novel approach to bioengineer artificial skin for burn victims

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Tercica files for patent infringement

European market for bone morphogenic proteins in spine fusion

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Importance of the phosphatidylinositol 3 kinase (PI3K) pathway to breast cancer development

Model may explain how alcohol stimulates tumor growth

Thiazolidinedione (TZD) class of anti-diabetic drugs may be a potential targeted therapy for myeloma patients

Class of cells that arises in mammary glands during maternity has stem cell-like properties

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Single dose phase I data on CG53135 for the prevention of oral mucositis

New trial to test cancer smart drugs

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News